IR
DPLO

Invictus RG’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Invictus RG’s Portfolio DPLO Stock Details DPLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,820
Closed -$286K – 573
2017
Q3 		$286K Buy
13,820
+2,707
+24% +$45.8K 0.26% 170
2017
Q2 		$164K Buy
+11,113
New +$185K 0.12% 313

Other funds holding DPLO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invictus RG's DPLO Position: Q4 2017 in Review

Invictus RG sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q4 2017, closing a stake of 13,820 shares — an estimated $286K sold.

Invictus RG first reported a position in DPLO in Q2 2017 and held it in 2 quarters. The position peaked at $286K in Q3 2017. 200 funds tracked by Wall St. Rank hold DPLO as of Q4 2017.

  • Invictus RG reported no remaining DIPLOMAT PHARMACY, INC. position as of Q4 2017 after selling out during the quarter.
  • Invictus RG sold 13,820 DIPLOMAT PHARMACY, INC. shares in Q4 2017, an estimated $286K.
  • Invictus RG first reported a position in DIPLOMAT PHARMACY, INC. in Q2 2017 and held it in 2 quarters.
  • Invictus RG's DIPLOMAT PHARMACY, INC. position peaked at $286K in Q3 2017.
  • 200 funds tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q4 2017.

Based on Invictus RG's 13F filing for Q4 2017, filed 13 Feb 2018.